US FDA clears PCI Biotech bile duct cancer drug
Perspectivas América Latina 2023 Emerging Trends & Growth
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
The U.S. FDA cleared PCI Biotech Holding ASA's investigational new drug application for fimaporfin for the treatment of inoperable bile duct cancer.
The clearance allows the company to include patients in the U.S. in its phase 2 clinical program for the drug, following early signs of efficacy in phase 1.
